AU2019243578B2 - Use of histone modifiers to reprogram effector T cells - Google Patents

Use of histone modifiers to reprogram effector T cells

Info

Publication number
AU2019243578B2
AU2019243578B2 AU2019243578A AU2019243578A AU2019243578B2 AU 2019243578 B2 AU2019243578 B2 AU 2019243578B2 AU 2019243578 A AU2019243578 A AU 2019243578A AU 2019243578 A AU2019243578 A AU 2019243578A AU 2019243578 B2 AU2019243578 B2 AU 2019243578B2
Authority
AU
Australia
Prior art keywords
cells
lymphocytes
teff
population
teff cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019243578A
Other languages
English (en)
Other versions
AU2019243578A1 (en
Inventor
Junmei Wang
Cassian Yee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Publication of AU2019243578A1 publication Critical patent/AU2019243578A1/en
Application granted granted Critical
Publication of AU2019243578B2 publication Critical patent/AU2019243578B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
AU2019243578A 2018-03-28 2019-03-28 Use of histone modifiers to reprogram effector T cells Active AU2019243578B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649265P 2018-03-28 2018-03-28
US62/649,265 2018-03-28
PCT/US2019/024693 WO2019191501A1 (en) 2018-03-28 2019-03-28 Use of histone modifiers to reprogram effector t cells

Publications (2)

Publication Number Publication Date
AU2019243578A1 AU2019243578A1 (en) 2020-10-15
AU2019243578B2 true AU2019243578B2 (en) 2025-11-20

Family

ID=68060769

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019243578A Active AU2019243578B2 (en) 2018-03-28 2019-03-28 Use of histone modifiers to reprogram effector T cells

Country Status (8)

Country Link
US (2) US12173317B2 (cg-RX-API-DMAC10.html)
EP (2) EP3773626B1 (cg-RX-API-DMAC10.html)
JP (2) JP7447011B2 (cg-RX-API-DMAC10.html)
KR (2) KR20200138325A (cg-RX-API-DMAC10.html)
CN (1) CN112105368A (cg-RX-API-DMAC10.html)
AU (1) AU2019243578B2 (cg-RX-API-DMAC10.html)
CA (1) CA3094375A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019191501A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
US12173317B2 (en) * 2018-03-28 2024-12-24 Board Of Regents, The University Of Texas System Use of histone modifiers to reprogram effector T cells
KR102069704B1 (ko) * 2018-05-16 2020-01-23 고려대학교 산학협력단 Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법
US20210290742A1 (en) * 2018-09-27 2021-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy
WO2021222479A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
KR20230019460A (ko) * 2020-05-29 2023-02-08 상하이 준셀 테라퓨틱스 컴퍼니 리미티드 종양 침윤 림프구의 종자세포 배지 및 이의 용도
GB202008957D0 (en) * 2020-06-12 2020-07-29 Autolus Ltd Culture medium
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药（香港）有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
US20250248946A1 (en) * 2022-04-15 2025-08-07 Turn Biotechnologies, Inc. Methods and compositions for immune cell rejuvenation and therapies using rejuvenated immune cells
EP4519418A1 (en) * 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164675A1 (en) * 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
CN117731763A (zh) * 2016-06-24 2024-03-22 麦克马斯特大学 过继细胞转移与溶瘤病毒组合疗法
BR112020018049A2 (pt) * 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso
US12173317B2 (en) * 2018-03-28 2024-12-24 Board Of Regents, The University Of Texas System Use of histone modifiers to reprogram effector T cells
CA3111384A1 (en) 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164675A1 (en) * 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAE ET AL., LEUKEMIA, vol. 32, no. 9, 22 February 2018 (2018-02-22), pages 1932 - 1947, DOI: 10.1038/s41375-018-0062-8 *
LOSCHINSKI ET AL., ONCOTARGET, vol. 9, no. 17, 7 February 2018 (2018-02-07), pages 13125 - 13138 *

Also Published As

Publication number Publication date
WO2019191501A9 (en) 2020-02-06
CN112105368A (zh) 2020-12-18
US20250145953A1 (en) 2025-05-08
JP2024037880A (ja) 2024-03-19
EP3773626B1 (en) 2026-01-28
CA3094375A1 (en) 2019-10-03
WO2019191501A1 (en) 2019-10-03
EP3773626A4 (en) 2022-01-05
JP7447011B2 (ja) 2024-03-11
AU2019243578A1 (en) 2020-10-15
JP2021519087A (ja) 2021-08-10
EP3773626A1 (en) 2021-02-17
US12173317B2 (en) 2024-12-24
US20210189337A1 (en) 2021-06-24
EP4722350A2 (en) 2026-04-08
KR20200138325A (ko) 2020-12-09
KR20260109954A (ko) 2026-07-13

Similar Documents

Publication Publication Date Title
US20250145953A1 (en) Use of histone modifiers to reprogram effector t cells
CN112204148B (zh) 具有增强功能的修饰的免疫细胞及其筛选方法
CN106661129B (zh) 对ssea4抗原具有特异性的嵌合抗原受体
US20250320306A1 (en) Methods for production of tissue resident memory-like t cells and use thereof
US20250352582A1 (en) Compositions and methods for targeting cd13 and tim-3 with car t cells to treat acute myeloid leukemia
EP3947471A1 (en) Tn-muc1 chimeric antigen receptor (car) t cell therapy
EP4304612A2 (en) Compositions and methods for assessing and treating t cell dysfunction
CN111166867B (zh) Pd-1泛素化激动剂的功能与用途
EP4514382A1 (en) Chimeric antigen receptor modified regulatory t cells for treating cancer
US20220168407A1 (en) Use of tumor-independent antigens in immunotherapies
WO2022271637A1 (en) Method for preserving developmental potential of immune cells used for adoptive cellular therapies
EP4509137A1 (en) A chimeric antigen receptor combinatorial multi-antigen targeted allogeneic t cell immunotherapy with reduced risk of t cell exhaustion, host versus graft rejection, and graft versus host disease
US20250333695A1 (en) Methods for optimizing t cell immunotherapeutic effector and memory function
US20240342280A1 (en) Optimizing t cell differentiation state with micrornas
WO2023240182A1 (en) Disruption of kdm4a in t cells to enhance immunotherapy
WO2024062138A1 (en) Immune cells comprising a modified suv39h1 gene

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)